Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.37 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18486669 | 0.86 | LPAR3 (0.47) | GRM4LPAR3LPAR2TYMSLMNA | |
| SCHEMBL887099 | 0.82 | GRM4 (0.41) | GRM4LPAR3LPAR2TYMS | |
| Phosphoric Acid SCHEMBL29213143 | 0.79 | MMP1 (0.33) | LPAR3LPAR2MEN1ALDH1A1KMT2A | |
| SCHEMBL9177461 | 0.78 | ALDH1A1 (0.41) | MEN1ALDH1A1KMT2ACYP1A2THRB | |
| SCHEMBL2237290 | 0.78 | GRM4 (0.41) | GRM4LPAR3LPAR2TYMS | |
| SCHEMBL3044700 | 0.77 | MEN1 (0.35) | LPAR3LPAR2MEN1ALDH1A1KMT2A | |
| SCHEMBL2052355 | 0.76 | CYP4F2 (0.56) | GRM4LPAR3LPAR2MEN1ALDH1A1 | |
| SCHEMBL580695 | 0.74 | ALDH1A1 (0.38) | MEN1ALDH1A1KMT2ACYP1A2THRB | |
| SCHEMBL9177295 | 0.74 | CYP4F2 (0.42) | MEN1ALDH1A1KMT2ACYP1A2THRB | |
| SCHEMBL9181629 | 0.74 | CYP4F2 (0.47) | MEN1ALDH1A1KMT2ACYP1A2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825354-B2 | OSTEOPOROSIS; RHEUMATIC DISEASES | WYETH HOLDINGS CORPORATION | 2004-11-30 | — | — | US | disclosed |
| EP-1147080-B1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | WYETH CORP (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20020147342-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-10-10 | — | — | US | disclosed |
| US-6340691-B1 | TREATMENT OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN CYANAMID COMPANY | 2002-01-22 | — | — | US | disclosed |
| EP-1147080-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000044713-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| US-4591651-A | Process for directly converting an aldehyde into an ethylene ester | AGRIFURANE S.A. (FR) | 1986-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147342-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors | MMP12, MMP17, MMP14 | GRM4 3777/4885LPAR3 2839/4885LPAR2 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.